Menopause
Conference Coverage
Postmenopausal hot flashes cut by 93% with novel nonhormonal treatment
The investigational neurokinin 3 receptor antagonist fezolinetant successfully and safely reduced hot flushes in postmenopausal women.
From the Journals
Study shows no adverse events with long-term denosumab in postmenopausal women
Denosumab, taken long term, is not linked with any adverse events, an analysis of the participants in the FREEDOM trial showed.
Conference Coverage
Neurokinin receptor antagonist nearly halves hot flashes
ORLANDO – The novel approach reduced hot flashes without the need for estrogen in a phase II trial.
Conference Coverage
Bioidentical hormone replacement fares well in phase III trial
ORLANDO – Phase III trial results represent another step toward FDA approval of a formulation of bioidentical hormone therapy to treat hot flashes...
Conference Coverage
HT use associated with lower postmenopausal coronary artery calcium scores
Could the lower postmenopausal coronary artery calcium scores seen in HT users be linked to lower all-cause mortality?
From the Journals
Older women with remitted depression show attention bias for negative information
A study of postmenopausal women shows those with remitted depression are more likely to process negative information than those with no depression...
Clinical Review
2016 Update on bone health
Prioritize bone health, as osteoporotic fracture is a major source of morbidity and mortality among women. In this article: fracture risk with OC...
News from the FDA/CDC
FDA approves vaginal insert to treat dyspareunia in menopause
It’s the first FDA-approved product containing the active ingredient prasterone, known also as DHEA. It will be marketed by Endoceutics Inc., a...
Feature
It’s not easy to identify clinical depression in menopause
Clinical depression isn’t a more severe extreme of milder depressive symptoms, but rather a distinct clinical entity, said Hadine Joffe, MD, and...
Feature
NAMS hormone therapy guidelines stress individualized treatment
The new statement, an update from the North American Menopause Society’s 2012 recommendations, gives targeted recommendations for special...
Feature
Odanacatib reduced fractures but upped stroke risk
Based on an independent analysis and verification of the risk for stroke, the drug’s sponsor, Merck, has withdrawn odanacatib from review by the...